WealthPLAN Partners LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 2.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,914 shares of the biopharmaceutical company’s stock after selling 1,803 shares during the quarter. WealthPLAN Partners LLC’s holdings in Pfizer were worth $2,613,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. NuWave Investment Management LLC boosted its stake in shares of Pfizer by 439.7% during the 3rd quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 1,196 shares during the period. Wolff Financial Management LLC boosted its stake in shares of Pfizer by 5.4% during the 3rd quarter. Wolff Financial Management LLC now owns 39,180 shares of the biopharmaceutical company’s stock worth $1,438,000 after acquiring an additional 2,014 shares during the period. Monument Capital Management boosted its stake in shares of Pfizer by 0.7% during the 3rd quarter. Monument Capital Management now owns 62,057 shares of the biopharmaceutical company’s stock worth $2,277,000 after acquiring an additional 402 shares during the period. Fieldpoint Private Securities LLC boosted its stake in shares of Pfizer by 5.8% during the 3rd quarter. Fieldpoint Private Securities LLC now owns 20,420 shares of the biopharmaceutical company’s stock worth $749,000 after acquiring an additional 1,120 shares during the period. Finally, Conestoga Capital Advisors LLC boosted its stake in shares of Pfizer by 2.3% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 17,508 shares of the biopharmaceutical company’s stock worth $643,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 67.36% of the company’s stock.
Several research analysts have recently commented on PFE shares. The Goldman Sachs Group set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, January 21st. Royal Bank of Canada set a $42.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Monday, January 4th. Barclays lifted their price target on Pfizer from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Friday, December 4th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Tuesday, November 10th. They set a “market perform” rating and a $42.00 price target for the company. Finally, Mizuho dropped their price target on Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $39.38.
Shares of Pfizer stock traded down $0.52 during trading on Tuesday, reaching $33.74. 817,955 shares of the company’s stock were exchanged, compared to its average volume of 35,504,273. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.13 and a current ratio of 1.40. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $43.08. The company has a market cap of $187.54 billion, a P/E ratio of 22.10, a PEG ratio of 2.79 and a beta of 0.70. The firm’s 50-day moving average price is $35.94 and its 200 day moving average price is $37.10.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The business had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. Pfizer’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period last year, the firm posted $0.55 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, January 28th. This represents a $1.56 dividend on an annualized basis and a yield of 4.62%. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s payout ratio is currently 52.88%.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Recommended Story: Percentage Gainers
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.